Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932 is registered in ClinicalTrials.gov with K36 Therapeutics, Inc. as lead sponsor.

NCT NCT05651932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05651932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
K36 Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 22, 2023
Completion date
June 30, 2028
Enrollment
165 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, myeloma, myeloma multiple